Blueprint Medicines

154 articles about Blueprint Medicines

• Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

  11/6/2019

  Blueprint Medicines to Host Investor Event and Webcast on Sunday, December 8, 2019

• Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

  11/5/2019

  R&D Day presentation discloses four research programs demonstrating the transformative science, urgency and efficiency underpinning the company's integrated precision medicine platform

• Blueprint Medicines to Host R&D Day and Announce Third Quarter 2019 Financial Results on November 5, 2019

  10/29/2019

  Blueprint Medicines Corporation announced that it will host a Research and Development Day for analysts and investors on Tuesday, November 5, 2019 beginning at 8:30 a.m. ET in New York City.

• Ipsen and Blueprint Medicines Announce Exclusive Global License Agreement to Develop and Commercialize BLU-782 for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

  10/16/2019

  Expands Ipsen’s Rare Diseases portfolio to include BLU-782, a highly selective investigational ALK2 inhibitor for the treatment of FOP

• Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

  8/7/2019

  Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for avapritinib

• Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference

  8/6/2019

  Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced that Andy Boral, M.D., Ph.D., Blueprint Medicines' Chief Medical Officer, will present a company overview at the 2019 Wedbush PacGrow Healthcare Conference in New York,

• Blueprint Medicines Reports Second Quarter 2019 Financial Results

  8/1/2019

  Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported financial results and provided a business update for the quarter ended June 30, 2019.

• Blueprint Medicines to Present at Upcoming Investor Conferences in June - May 29, 2019

  5/29/2019

  Blueprint Medicines Corporation announced its participation in the following upcoming investor conferences

• Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis

  12/2/2018

  83% overall response rate, with evidence of deepening of response over time

• Blueprint Medicines Announces Updated NAVIGATOR Trial Results in Patients with Advanced Gastrointestinal Stromal Tumors Supporting Development of Avapritinib Across All Lines of Therapy

  11/15/2018

  84% ORR in PDGFRα D842V GIST and 20% ORR in fourth-line or later GIST support plans to submit New Drug Application to FDA in the first half of 2019

• Blueprint Medicines Strengthens Leadership with the Appointments of Christina Rossi as Chief Commercial Officer and Paul Beresford as General Manager, International

  10/29/2018

  Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christina Rossi as Chief Commercial Officer, effective October 29, 2018. Blueprint Medicines also announced the appointment of Paul Beresford as General Manager, International.

• Blueprint Medicines to Report Third Quarter 2018 Financial Results on Tuesday, October 30, 2018

  10/23/2018

  Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, October 30, 2018 to report its third quarter 2018 financial results and provide a corporate update.

• Blueprint Medicines Announces Updated Data from Phase 1 ARROW Clinical Trial Showing Broad, Durable Activity of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers

  10/6/2018

  90 percent of evaluable MTC and PTC patients had tumor reductions

• Blueprint Medicines to Present at Upcoming Investor Conferences in August 2018

  8/1/2018

  Blueprint Medicines Corporation announced its participation in the following upcoming investor conferences:

• Blueprint Medicines Reports Second Quarter 2018 Financial Results

  8/1/2018

  Presented Data from Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Overall Response Rate of 83% and Durable Ongoing Reponses up to 22 Months

• Blueprint Medicines to Report Second Quarter 2018 Financial Results on Wednesday, August 1, 2018

  7/25/2018

  Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 1, 2018 to report its second quarter 2018 financial results and provide a corporate update.

• Blueprint Medicines Initiates VOYAGER Phase 3 Clinical Trial of Avapritinib in Patients with Advanced Gastrointestinal Stromal Tumors

  6/21/2018

  -- VOYAGER trial to evaluate avapritinib versus regorafenib in third- and fourth-line GIST --

• Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity

  6/15/2018

  Overall Response Rate of 83%

• Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors

  6/7/2018

  Orchard Therapeutics today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of directors as independent directors.

• Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China

  6/4/2018

  Blueprint Medicines Corporation and CStone Pharmaceuticals announced an exclusive collaboration and license agreement for the development and commercialization of avapritinib, BLU-554 and BLU-667 in Mainland China, Hong Kong, Macau and Taiwan.